Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at ...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
